Extended-Release Calcifediol Effectively Raises Serum Total 25-Hydroxyvitamin D Even in Overweight Nondialysis Chronic Kidney Disease Patients with Secondary Hyperparathyroidism.

Bishop, Charles W; Strugnell, Stephen A; Csomor, Philipp; Kaiser, Edelgard; Ashfaq, Akhtar

Bishop, Charles W; Strugnell, Stephen A; Csomor, Philipp; Kaiser, Edelgard; Ashfaq, Akhtar.

Affiliation

Bishop CW; Renal Division, OPKO Health, Inc., Miami, Florida, USA.
Strugnell SA; Renal Division, OPKO Health, Inc., Miami, Florida, USA.
Csomor P; Vifor Pharma, Ltd., Zurich, Switzerland.
Kaiser E; Vifor Pharma, Ltd., Zurich, Switzerland.
Ashfaq A; Renal Division, OPKO Health, Inc., Miami, Florida, USA.

Am J Nephrol ; 53(6): 446-454, 2022.

Article in En | MEDLINE | ID: mdl-35551374

Subject(s)

Hyperparathyroidism, Secondary; Renal Insufficiency, Chronic; Vitamin D Deficiency; Calcifediol; Cholecalciferol/therapeutic use; Ergocalciferols/therapeutic use; Humans; Hyperparathyroidism, Secondary/complications; Hyperparathyroidism, Secondary/etiology; Overweight/complications; Overweight/drug therapy; Parathyroid Hormone; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic/complications; Renal Insufficiency, Chronic/drug therapy; Vitamin D/analogs & derivatives; Vitamin D Deficiency/complications; Vitamin D Deficiency/drug therapy; Vitamins/therapeutic use

Key words

Body mass index; Body weight; Chronic kidney disease; Extended-release calcifediol; Obesity; Secondary hyperparathyroidism; Vitamin D

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Vitamin D Deficiency / Renal Insufficiency, Chronic / Hyperparathyroidism, Secondary Type of study: Clinical_trials / Etiology_studies Language: En Journal: Am J Nephrol Year: 2022 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google